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Summary. Background: Venous thromboembolism (VTE) is a frequent complication in cancer patients receiving adjuvant treatment. The risk of VTE during neoadjuvant chemo-radiotherapy remains unclear. Objectives: This systematic review evaluated the incidence of VTE in patients with cancer receiving neoadjuvant treatment. Methods: MEDLINE and EMBASE databases were searched from inception to October 2017. Search results were supplemented with screening of conference proceedings of the American Society of Clinical Oncology (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) and the International Society of Thrombosis and Haemostasis (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . Two review authors independently screened titles and abstracts, and extracted data onto standardized forms. Results: Twenty-eight cohort studies (7827 cancer patients, range 11 to 1398) were included. Twenty-five had a retrospective design. Eighteen cohorts included patients with gastrointestinal cancer, representing over two-thirds of the whole study population (n = 6002, 78%). In total, 508 of 7768 patients were diagnosed with at least one VTE during neoadjuvant treatment, for a pooled VTE incidence of 7% (95% CI, 5% to 10%) in the absence of substantial between-study heterogeneity. Heterogeneity was not explained by site of cancer or study design characteristics. VTE presented as pulmonary embolism in 22% to 96% of cases (16 cohorts) , and it was symptomatic in 22% to 100% of patients (11 cohorts) . The highest VTE rates were observed in patients with bladder (10.6%) or esophageal (8.4%) cancer. Conclusions: This review found a relatively high incidence of VTE in cancer patients receiving neoadjuvant therapy in the presence of some between-study variation, which
Introduction
Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a frequent complication in patients with solid or hematological malignancies [1] . The procoagulant state associated with cancer disease and cancer treatments increase the risk of VTE up to 50-fold compared with patients without cancer [1] [2] [3] [4] [5] [6] [7] .
Although the risk of VTE has been well described in cancer patients from adjuvant and palliative settings, data on the occurrence of VTE in patients receiving neoadjuvant chemo-radiotherapy remain limited and conflicting [5] . Even though cancer may be considered as less extensive in the neoadjuvant setting and therefore amenable to surgical excision, certain tumor types with a high thrombogenic potential, such as gastric or pancreatic cancer, could activate blood coagulation, leading to thrombosis [1, 8] . In addition, neoadjuvant chemotherapy may increase the risk of VTE by directly damaging the endothelium, reducing the levels of blood anticoagulants, and increasing tissue factor activity [8] . The occurrence of VTE during these early phases of cancer disease may have a significant impact on morbidity, cause the interruption of neoadjuvant treatment, delay surgery and increase health resources utilization and costs.
Current guidelines suggest the use of VTE thromboprophylaxis in high-risk cancer patients receiving adjuvant chemotherapy, whereas no specific recommendations are provided for patients undergoing neoadjuvant chemoradiotherapy [9] . A better understanding of VTE risk during neoadjuvant treatment may inform oncologists about thrombotic risk in these patients, and potentially provide useful information to design randomized controlled studies of VTE thromboprophylaxis with the aim of reducing this burdensome complication.
The aim of this review was to summarize the evidence on the risk of VTE in ambulatory cancer patients receiving neoadjuvant chemotherapy or chemo-radiotherapy.
Methods
A systematic search of the literature was conducted in the MEDLINE and EMBASE electronic databases (from inception to October 2017). Conference proceedings of the American Society of Clinical Oncology (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) and the International Society of Thrombosis and Haemostasis (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) were screened for potentially relevant records. We used the following search terms as text and Mesh words for the search in the electronic databases: 'neoadjuvant therapy', 'perioperative chemotherapy', 'thrombosis', 'pulmonary embolism', 'venous thromboembolism' and 'venous thrombosis'. We applied no language restriction. The search results were supplemented with screening of citation lists of related reviews and those of included studies. The review is registered in PROSPERO with accession number CRD42017080148.
Study selection
Prospective or retrospective cohort studies and randomized controlled trials reporting on the incidence of VTE during neoadjuvant chemotherapy or chemo-radiotherapy in patients with cancer were eligible. We excluded studies reporting on a mix of arterial and venous thrombotic complications as well as studies that evaluated the occurrence of VTE over the entire perioperative period if the incidence of VTE could not be extracted separately for the presurgical neoadjuvant phase. In addition, studies occasionally reporting on VTE as one of the adverse effects of chemotherapy were not considered as these studies may selectively report only more severe cases or fail to properly identify and classify thrombotic events.
Two review authors (MDN and MC) independently screened the titles and abstracts identified from the searches and any disagreements were resolved through discussion. Studies with insufficient information were reevaluated if additional data were made available from the trial authors.
Data extraction
Two review authors (MDN and MC) independently extracted the data from included studies onto standardized forms, resolving any disagreements through discussion or by involving a third review author (AR). We extracted data on patients' characteristics (e.g. age and gender), type of cancer and neoadjuvant treatment (chemotherapy, radiotherapy, or both), incidence and type of VTE (PE or DVT of the lower or upper extremities), presentation of VTE (symptomatic vs. incidentally detected) and use of thromboprophylaxis during neoadjuvant treatment. The main outcome of interest was any VTE, which included symptomatic or incidentally detected DVT and PE. The components of the main outcome were considered as secondary outcomes.
Study quality assessment
For each of the included studies, we evaluated the risk of bias using the Quality in Prognosis Studies (QUIPS) tool, which considers six domains to evaluate the validity of and bias in prognostic studies. Domains are related to: (i) study participation, addressing the representativeness of the study population; (ii) attrition bias; (iii) adequacy of prognostic factor measurement; (iv) adequacy of outcome measurement; (v) study confounding, which addresses potential confounding factors, and (vi) appropriateness of statistical analysis and completeness of reporting [10] . Each of these domains was rated as at high, moderate, low or unclear risk of bias. The latter category was only used if insufficient details were reported to allow a judgment. We followed guidance as outlined by Hayden and colleagues [10] , and only describe review-specific rules for interpretation here. The domain 'prognostic factor measurement' was considered at 'low risk of bias' if information was provided on the type, dose and duration of neoadjuvant treatment. Regarding the domain related to attrition, we anticipated that retrospective cohort studies could select cancer patients undergoing surgery after neoadjuvant treatment. Because the evaluation of attrition bias in these circumstances would be hampered by the lack of information on withdrawals and patients who did not reach the surgical phase, we rated this domain as moderate risk in such studies. The interpretation of the domain 'adequacy of outcome measurement' was focused on the primary outcome of any VTE and considered to be adequate if VTE was objectively diagnosed using reliable and valid reference tests in all participants [11] . For the domain related to confounding, we considered the handling of potential confounders such as previous VTE, use of central vein catheters, performance status and use of thromboprophylaxis during neoadjuvant treatment. We used the GRADE methodology to judge the overall quality of the evidence [12] .
Statistical analysis
In descriptive analyses, continuous variables were reported as mean (AE standard deviations) or median (range) and categorical variables as number (percentages). Confidence intervals around proportions were calculated with the Wilson method. We used univariate random effects logistic regression models to summarize VTE incidences as proportions and univariable meta-regression to evaluate the effect of cancer type and QUIPS domains.
The likelihood ratio test was used to compare models with and without a specific covariate. All statistical analyses were conducted using STATA version 15.1 (STATACorp LLC, College Station, Texas, USA). 
Results
The initial search yielded 944 references. Four additional records were identified by screening of conference proceedings and references lists (Fig. 1) . Following title and abstract screening, 902 records were excluded and 46 considered potentially eligible. After full-text examination, 18 were excluded because outcome data could not be extracted separately for patients receiving neoadjuvant treatment (n = 4) or the article reported a mix of arterial and venous thrombotic events (n = 14). Twenty-eight records (19 full texts and nine abstracts) including a total study population of 7827 cancer patients (range 11 to 1398 patients) were finally included in the review (Table 1 ) . All studies but two were single center [21, 37] and were conducted during a time period that spanned from 1994 to 2015. Three studies (10%) had a prospective design [22, 38, 40] and all others concerned retrospective cohorts. Overall study quality was modest, with no study judged to be at low risk of bias across all QUIPS domains. We adjudicated domains of the QUIPS tool as at moderate or high risk of bias in 55% up to 100% of the studies (Table 2) .
Eighteen cohorts included patients with gastrointestinal cancer, representing over two-thirds of the whole study population (n = 6002, 78%). Eight studies evaluated cancer of the genitourinary tract, whereas cancer of the lung, breast and soft tissue were included in one study each. The type of neoadjuvant treatment is shown in the Supplementary Table. Venous thromboembolism during neoadjuvant treatment
In total, 508 of 7768 patients were diagnosed with at least one VTE during neoadjuvant treatment, for an overall mean VTE incidence of 7% (95% CI, 5% to 10%; moderate quality of evidence due to risk of bias). There was low between-study heterogeneity; the variation observed was mainly attributed to chance (Fig. 2) . Rates of VTE varied across studies, ranging from less than 1% up to 28% (Fig. 2) . The highest risk of VTE was observed in patients with bladder (13%; 95% CI, 6% to 21%) or esophageal (7%; 95% CI, 5% to 10%) cancer (Table 3) . Figure 3 shows the impact of cancer type, study design and risks of bias in the six QUIPS domains. Although VTE incidence seemed higher in genitourinary cancer and in studies at low risk of bias concerning patient participation, the evidence was weak. No differences were observed on any of the study quality domains (Fig. 3) . Sixteen cohorts reported on the site of thrombosis and 11 indicated whether VTE was symptomatic or incidentally detected (Table 3) . The proportion of patients presenting with PE varied between 22% and 96%, whereas that of symptomatic VTE ranged from 22% to 100%. The majority of symptomatic events were DVTs (38/63). Only nine of the 25 studies including patients with genitourinary or gastrointestinal cancer described the clinical presentation of VTE, which was reported to be
Gastrointestinal cancers Amada (2016) Berger (2005) Bosch (2014) Khanna (2014) Krepline (2016) Larsen (2015) Mezi (2013) Mohan (2016) Mungo (2014) Muthiah (2012) O'Connor (2015) Rollins (2011) Rulach (2016) Sabra (2016) Smart (2015) Teman (2012) Tetzlaff (2008) Wada ( Bagrodia (2016) Duivenvoorden (2016) Greco (2017) Pugashetti (2016) Syed ( (Table 3 ). In the study by Krepline and colleagues, 18% of patients with pancreatic cancer were receiving or started VTE thromboprophylaxis at the time of cancer diagnosis [30] . VTE thromboprophylaxis was not provided during neoadjuvant treatment in 15 studies, whereas information about the use of thromboprophylaxis was lacking in all other cohorts.
Three studies adopted a screening strategy for VTE, which included the systematic evaluation of patients by compression ultrasonography [18, 22, 38] or computed tomography pulmonary angiography [22] before and at the end of neoadjuvant treatment.
Additional observations
Eight studies reported on the prevalence of VTE before the start of neoadjuvant treatment, which ranged between less than 1% up to 10% [17, 21, 22, 26, [29] [30] [31] 36] . The clinical presentation of prevalent VTE was described only by Krepline and colleagues, who reported that 69% of these events were incidentally detected [30] .
The performance of the Khorana score for the prediction of VTE during neoadjuvant treatment was evaluated in two studies [30, 31] . In patients with pancreatic cancer, the incidence of VTE was 10% (15/155) in patients classified by the Khorana score as at intermediate risk and 11% (11/101) in those at high risk [30] . Similar findings were reported in the other study on patients with genitourinary cancer (3/28 vs. 5/42, respectively) [31] .
No study reported on the incidence of bleeding that occurred either spontaneously or during thromboprophylaxis during the neoadjuvant period. In the study by Rulach and colleagues, there were two fatal and three non-fatal bleeding events, which, however, occurred during anticoagulant treatment for newly diagnosed VTE. 
Discussion
This review found a relatively high incidence of VTE in cancer patients receiving neoadjuvant therapy, with apparently higher VTE rates for cancer of the bladder or esophagus. Information on the site and clinical presentation of VTE was scanty and highly heterogeneous across studies. Two-thirds of the study population were represented by patients with gastroesophageal or bladder cancer, with limited or no data available for cancers at other sites. Although VTE represents a common complication in patients with cancer, the risk varies markedly among these patients depending on cancer stage and the presence of a number of clinical and laboratory risk factors [1, 5] . Chemotherapy increases the risk of VTE by 2-to 6-fold and specific chemotherapeutic agents, such as platinumbased regimens, have been associated with higher rates of VTE [2, 4, 7] . The risk of VTE in patients with a less advanced stage of cancer undergoing neoadjuvant chemotherapy is less well established. In a study population of over 7800 patients, we found a 7% pooled incidence of VTE, consistent with rates observed in ambulatory cancer patients receiving adjuvant treatment [6, 8, 41] . In a recent narrative review of studies on patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy, Marshall-Webb and colleagues reported an incidence of VTE ranging between 4% and 19% [42] . The inclusion of studies reporting VTE incidence throughout the neoadjuvant and postoperative periods limits the interpretation of their findings.
The primary site of cancer has been identified as a significant risk factor for VTE across a variety of studies [5] . Fig. 3 . Incidence of venous thromboembolism according to cancer type, study design and risks of bias domains. GI, gastrointestinal; GU, genitourinary; QUIPS, Quality in Prognosis Studies tool used for risk of bias assessments in prognostic studies.
Although specific incidence rates vary based on the clinical setting, cancer types consistently associated with the highest rates of VTE include those of the pancreas, stomach, uterus, kidney, lung and primary brain [1, 5, 43] . These cancer types could be associated with a procoagulant state even when diagnosed at an earlier stage. As two-thirds of the current review population was represented by patients with gastrointestinal cancer, the high incidence of VTE observed in our study may be driven by the inclusion of a large proportion of these highly thrombogenic cancer types.
About half of all VTEs diagnosed in cancer patients undergoing adjuvant chemotherapy are incidentally detected [44] . Although it is still an area of investigation and debate, data suggest that incidental VTE in the cancer population has important prognostic implications and clinical practice guidelines recommend the same anticoagulant treatment as for symptomatic VTE [9, 45] . In the current review, the proportion of patients presenting with an incidental VTE varied across studies, and the variation was insufficiently explained by cancer type, study design or risk of bias domains.
This review has some limitations that need to be acknowledged. Although we used robust methods of double and independent risk of bias assessment, poor reporting may have led to some misclassifications. For example, clinical presentation of VTE was reported by only onethird of the studies, and information on the diagnostic VTE work-up was lacking or poorly described. All studies included were judged to have significant methodological flaws. The lack of systematic VTE diagnosis by an accepted reference method may have introduced significant bias. We found moderate quality for the incidence of VTE, where we downgraded the evidence for risk of bias, in the absence of substantial inconsistency, imprecision or indirectness. Although study estimates seemed to vary across studies and within each cancer type, this was mainly explained by chance. We are moderately confident that the actual incidence is close to the estimate, but there is a possibility that it is substantially different [12] . Information on study population characteristics and concomitant VTE risk factors was scarce, and significant residual confounding cannot be excluded. Most of the studies were relatively old and the observed VTE rates may not apply to patients undergoing contemporary neoadjuvant treatments. Poor reporting on the use of thromboprophylaxis and outcome verification may have resulted in significant underestimation of VTE incidence. Finally, the predominant inclusion of gastroesophageal and bladder cancer, limits the generalizability of these findings to cancer at other sites.
In conclusion, the risk of VTE in cancer patients undergoing neoadjuvant treatments appears to be not negligible. Future large prospective studies are warranted to clarify the actual burden of VTE and the potential efficacy and safety of VTE thromboprophylaxis in this setting.
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